이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Pieris Pharmaceuticals 관리
관리 기준 확인 3/4
Pieris Pharmaceuticals' CEO는 Steve Yoder, Dec2014 에 임명되었습니다 의 임기는 9.5 년입니다. 총 연간 보상은 $ 1.36M, 43% 로 구성됩니다. 43% 급여 및 57% 보너스(회사 주식 및 옵션 포함). 는 $ 692.53 가치에 해당하는 회사 주식의 0.006% 직접 소유합니다. 692.53. 경영진과 이사회의 평균 재임 기간은 각각 4.7 년과 6.6 년입니다.
주요 정보
Steve Yoder
최고 경영자
US$1.4m
총 보상
| CEO 급여 비율 | 43.0% |
| CEO 임기 | 9.6yrs |
| CEO 소유권 | 0.006% |
| 경영진 평균 재임 기간 | 4.8yrs |
| 이사회 평균 재임 기간 | 6.7yrs |
최근 관리 업데이트
Recent updates
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$585k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$28m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$2m | US$565k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$42m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$2m | US$548k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$48m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$2m | US$535k | -US$37m |
| Sep 30 2020 | n/a | n/a | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$2m | US$515k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$36m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$28m |
| Dec 31 2018 | US$3m | US$500k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$18m |
| Dec 31 2017 | US$1m | US$450k | -US$18m |
보상 대 시장: Steve 의 총 보상 ($USD 1.36M )은 US 시장( $USD 683.56K ).
보상과 수익: Steve 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Steve Yoder (48 yo)
9.6yrs
테뉴어
US$1,358,952
보상
Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, President & Director | 9.6yrs | US$1.36m | 0.0057% $ 735.7 | |
| Senior VP | 4.8yrs | US$729.04k | 0.018% $ 2.4k | |
| Senior VP & Chief Development Officer | no data | US$705.45k | 0.0044% $ 568.6 | |
| Executive Director of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Chief Supply Chain Officer | 4.8yrs | 데이터 없음 | 데이터 없음 | |
| VP and Head of Alliance Management & Early Project Leadership | 1.5yrs | 데이터 없음 | 데이터 없음 |
4.8yrs
평균 재임 기간
48yo
평균 연령
경험이 풍부한 관리: PIRS 의 관리팀은 경험 ( 4.7 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, President & Director | 9.6yrs | US$1.36m | 0.0057% $ 735.7 | |
| Independent Chairman | 7.2yrs | US$94.09k | 0.019% $ 2.5k | |
| Independent Director | 9.6yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$72.58k | 0.019% $ 2.5k | |
| Independent Director | 5.8yrs | US$65.08k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$53.09k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 5yrs | US$52.09k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | 데이터 없 음 | 데이터 없음 | |
| Member of Clinical & Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Clinical & Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Clinical & Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 |
6.7yrs
평균 재임 기간
61.5yo
평균 연령
경험이 풍부한 이사회: PIRS 의 이사회는 경험(평균 재직 기간 6.6 년)으로 간주됩니다.